Noopept vs Substance P

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Noopept

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a peptide-derived nootropic developed in Russia. While technically a dipeptide prodrug rather than a true peptide, it's often discussed alongside peptide nootropics.

Full details →

Substance P

Substance P is an 11-amino acid neuropeptide involved in pain transmission, inflammation, and various neurological processes. While not used therapeutically itself, understanding it is crucial for pain research.

Full details →

Side-by-Side Comparison

Aspect	Noopept	Substance P
Dose Range	10 mg–30 mg	35 mcg–350 mcg
Frequency	2x daily	1x daily
Cycle Length	4–6 weeks	1 weeks
Route	oral	subcutaneous
Mechanism	Metabolized to cycloprolylglycine which modulates AMPA and NMDA receptors, increases NGF and BDNF expression, and provides neuroprotective effects through antioxidant mechanisms.	Binds primarily to NK1 receptors to transmit pain signals from peripheral nerves to the CNS. Also promotes inflammation, causes vasodilation, and stimulates immune cells.
Typical Dosage	Oral: 10-30mg daily, typically divided into 2-3 doses. Sublingual use may enhance absorption. Some users go higher but effects may plateau.	Not used as a therapeutic agent. NK1 receptor antagonists (blocking Substance P) are used clinically for chemotherapy-induced nausea.
Administration	Oral or sublingual administration. Unlike most peptides, it's orally bioavailable. Can be taken with or without food.	Research compound only. Therapeutic applications focus on blocking rather than administering Substance P.
Side Effects	Headache (often from choline depletion), irritability, insomnia if taken late, and occasional brain fog during initial use.	Administration would cause pain, inflammation, and neurogenic responses. Not given therapeutically.
Best For	Cognitive Performance	Cognitive Performance